Skip to main content
. 2017 May 7;8(29):47507–47517. doi: 10.18632/oncotarget.17670

Figure 2. AUROC of pre-treatment WFA+-M2BP for HCC prediction in CHB patients.

Figure 2

(A) CHB patients (whole cohort); (B) CHB patients with cirrhosis; (C) CHB patients without cirrhosis; Abbreviations: AUROC, area under receiveroperating curve; WFA+-M2BP, Wisteria floribunda agglutinin-positive human Mac-2 binding protein; HCC, hepatocellular carcinoma; CHB, chronic hepatitis B.